# Integer Holdings Corp: Form 10-Q for the period ended Jul 2, 2010

- Company: [Integer Holdings Corp](/companies/itgr.md) (CIK 1114483)
- Form: 10-Q
- Filed: 2010-08-10
- Accepted by EDGAR: Aug 10, 2010, 10:01 ET
- Period: 2010-07-02
- Accession: 0000950123-10-075320
- Inline XBRL: no
- Main document: https://www.sec.gov/Archives/edgar/data/1114483/000095012310075320/c04621e10vq.htm
- All documents and exhibits: https://www.sec.gov/Archives/edgar/data/1114483/000095012310075320/

## Management's discussion and analysis

As filed, 46,536 characters.

### Our Business

We operate our business in two reportable segments — Greatbatch Medical and Electrochem Solutions (“Electrochem”). Greatbatch Medical designs and manufactures systems, components and devices for the cardiac rhythm management (“CRM”), neuromodulation, vascular and orthopaedics markets. Greatbatch Medical customers include large multi-national original equipment manufacturers (“OEMs”). Greatbatch Medical products include: 1) batteries, capacitors, filtered and unfiltered feedthroughs, engineered components and enclosures used in implantable medical devices (“IMDs”); 2) introducers, catheters, steerable sheaths and implantable stimulation leads; and 3) instruments and delivery systems used in hip and knee replacement, trauma and spine surgeries as well as hip, knee and shoulder implants. Additionally, Greatbatch Medical offers value-added assembly and design engineering services for medical systems and devices within the markets in which it operates.

Electrochem provides technology solutions for critical industrial applications, including customized battery power and wireless sensing systems. Originating from the lithium cell invented for the implantable pacemaker by our Company’s founder, Wilson Greatbatch, Electrochem’s technology and superior quality and reliability is utilized in markets world-wide.

### Our Customers

Greatbatch Medical customers include leading OEMs, in alphabetical order here and throughout this report, such as Biotronik, Boston Scientific, DePuy, Johnson & Johnson, Medtronic, Smith & Nephew, Sorin Group, St. Jude Medical, Stryker and Zimmer. The nature and extent of our selling relationships with each OEM varies in terms of breadth of products purchased, purchased product volumes, length of contractual commitment, ordering patterns, inventory management and selling prices. During the six months ended July 2, 2010, Boston Scientific, Johnson & Johnson, Medtronic and St. Jude Medical collectively accounted for 61% of our total sales.

\- 25 -

The initial term of our supply agreement with Boston Scientific pursuant to which Boston Scientific purchases a certain percentage of the batteries, capacitors, filtered feedthroughs and case halves it uses in its IMDs ends on December 31, 2010. The agreement may be renewed for one or more four-year renewal terms upon mutual agreement of the parties. We are actively negotiating a follow-on agreement with targeted completion during 2010.

In June 2010, we extended our feedthrough agreement with St. Jude Medical through 2017. Under the terms of the agreement we are guaranteed 100% of St Jude Medical’s feedthrough and filtering business and 80% of their implantable pulse generator MRI filtered feedthrough business. This agreement demonstrates the close working relationship we have with our customers and more specifically, St. Jude Medical. Additionally, it is a testament to our quality and reliability as we have been named the exclusive supplier of this key component to St. Jude Medical’s devices.

Our Electrochem customers operate in the energy, security, portable medical and environmental monitoring markets and include 3M, General Electric, Halliburton, Honeywell, Thales, Weatherford and Zoll Medical.

### Financial Overview

Sales for the second quarter of 2010 were $140.8 million compared to $134.7 million in the comparable 2009 period. This 5% increase was primarily due to improvements in our vascular and Electrochem markets, which were negatively impacted in the 2009 period by customer inventory adjustments and a contraction in the underlying markets which have now begun to ease. For the first half of 2010, sales of $273 million were consistent with the prior year period.

We prepare our financial statements in accordance with generally accepted accounting principles in the United States of America (“GAAP”). Additionally, we consistently report and discuss in our quarterly earnings releases and investor presentations adjusted operating income and margin, adjusted net income and adjusted earnings per diluted share. These adjusted amounts consist of GAAP amounts excluding the following adjustments to the extent they occur during the period: (i) acquisition-related charges; (ii) facility consolidation; manufacturing transfer and system integration charges; (iii) asset write-down and disposition charges; (iv) litigation charges; (v) the non-cash impact of accounting changes and (vi) the income tax (benefit) related to these adjustments. We believe that reporting these amounts provides important supplemental information to our investors and creditors seeking to understand the financial and business trends relating to our financial condition and results of operations. Additionally, performance-based compensation of our executive management is determined utilizing these adjusted amounts.

GAAP operating income for the second quarter of 2010 was $17.3 million compared to $12.5 million for the 2009 second quarter. Similarly, adjusted operating income was $17.8 million, or 12.7% of sales, in the second quarter 2010, compared to $14.9 million, or 11.1% of sales, for the comparable 2009 period. The increase in GAAP and adjusted operating income from the prior year was primarily due to higher revenue levels, as described above, partially offset by an increase in net research, development and engineering costs (“RD&E”), which, as expected, were higher in the current year period due to further investment in the development of new technologies, including systems level projects, in order to create long-term growth opportunities. Additionally, operating income benefited in the current period from a lower level of selling, general and administrative expenses (“SG&A”) due to our various consolidation and cost cutting initiatives.

\- 26 -

For the first six months of 2010, GAAP operating income was higher than the prior year period primarily due to lower consolidation and integration charges as those projects were substantially completed by the end of 2009. Adjusted operating income for the first six months of 2010 was consistent with the prior year period, as a higher level of RD&E costs was offset by lower SG&A expenses primarily due to the same reasons as discussed above.

A reconciliation of GAAP operating income to adjusted amounts is as follows (in thousands):

|  | Three Months Ended July 2, 2010 | July 3, 2009 | Six Months Ended July 2, 2010 | July 3, 2009 |
| --- | ---: | ---: | ---: | ---: |
| Operating income as reported | $17,317 | $12,469 | $31,313 | $27,268 |
| Adjustments: |  |  |  |  |
| Consolidation costs | 536 | 1,578 | 856 | 3,477 |
| Integration expenses | 8 | 717 | 130 | 1,580 |
| Asset dispositions and other | (49) | 129 | 501 | 170 |
| Adjusted operating income | $17,812 | $14,893 | $32,800 | $32,495 |
| Adjusted operating margin | 12.7% | 11.1% | 12.0% | 11.8% |

This higher level of GAAP and adjusted operating income for the 2010 periods was offset by a higher effective tax rate than the prior year periods due to the favorable impact of the resolution of tax audits during the 2009 second quarter and the expiration of the U.S. R&D tax credit at the end of 2009. As a result, GAAP diluted earnings per share (“EPS”) was $0.57 per share for the first six months of 2010 compared to $0.56 for the 2009 period. Similarly, adjusted diluted EPS was $0.71 for the first six months of 2010 versus $0.80 for the comparable 2009 period.

A reconciliation of GAAP net income and diluted EPS to adjusted amounts is as follows (in thousands):

|  | Three Months Ended July 2, 2010 | July 3, 2009 | Six Months Ended July 2, 2010 | July 3, 2009 |
| --- | ---: | ---: | ---: | ---: |
| Income before taxes as reported | $11,981 | $8,145 | $20,515 | $17,873 |
| Adjustments: |  |  |  |  |
| Consolidation costs | 536 | 1,578 | 856 | 3,477 |
| Integration expenses | 8 | 717 | 130 | 1,580 |
| Asset dispositions and other | (49) | 129 | 501 | 170 |
| CSN II conversion option discount amortization | 1,950 | 1,810 | 3,865 | 3,588 |
| Adjusted income before taxes | 14,426 | 12,379 | 25,867 | 26,688 |
| Adjusted provision for income taxes | 5,049 | 3,065 | 9,053 | 7,732 |
| Adjusted net income | $9,377 | $9,314 | $16,814 | $18,956 |
| Adjusted diluted EPS | $0.40 | $0.40 | $0.71 | $0.80 |
| Number of shares | 23,926 | 23,855 | 23,946 | 23,900 |

\- 27 -

Cash flows from operations for the first six months of 2010 were $44.2 million compared to $21.7 million for the 2009 period. The increase from the prior year is primarily due to our strategic initiatives designed to improve operational efficiency, as well as the timing of payments and lower consolidation and integrations costs. A portion of these cash flows from operations were used to repay the current portion of long-term debt of $30 million, which came due during the second quarter of 2010. The Company currently expects that cash flow from operations for the remainder of 2010 will continue to be used to support routine capital expenditures and to further pay down debt as we continue to take steps to strengthen our balance sheet in order to support future internal growth.

### Our CEO’s View

Our revenue and operating results for the second quarter of 2010 reflect improvements across all of our product lines, as well as continued benefits from our diversification strategy and our various cost cutting initiatives. We were especially pleased with the growth we saw in our vascular and Electrochem markets, which are recovering from the difficult market conditions of 2009. As we look to the second half of the year, we remain on track to meet our previously stated guidance. With that said, further sequential growth may prove to be challenging given our seasonally slow third quarter, foreign currency headwinds, and that customers have stabilized their inventory levels. Nevertheless, we continue to invest and take steps to deliver innovative solutions to our customers, including the continued development of systems level projects, which will be critical to our long-term growth and profitability. We remain confident in this strategy and continue to make significant progress towards the completion of these initiatives.

### Government Regulation

In March 2010, President Obama signed into law the Patient Protection and Affordable Care Act and the Health Care and Education Affordability Reconciliation Act (collectively “Health Care Reform”) legislating broad-based changes to the U.S. health care system. Health Care Reform could significantly impact our business operations and financial results, including higher or lower revenue, as well as higher employee medical costs and taxes. Many significant parts of the legislation will be phased in over the next eight years and require further guidance and clarification in the form of regulations. As a result, many of the impacts of Health Care Reform will not be known until those regulations are enacted, which we expect to occur over the next several years.

### Product Development

Currently, we are developing a series of new products for customer applications in the CRM, neuromodulation, vascular, orthopaedics and Electrochem markets. Some of the key development initiatives include:

1\. To develop complete system solutions for our OEM customers in the markets we operate in;

2\. To continue development of MRI compatible leadwires and other neuromodulation products;

3\. To continue development of higher energy/higher density capacitors;

4\. To integrate Biomimetic coating technology with our therapy delivery devices;

5\. To complete the design of next generation steerable catheters, sheaths and introducers;

6\. To further develop minimally invasive surgical techniques for the orthopaedics industry;

7\. To develop disposable instrumentation for the orthopaedics industry;

8\. To provide wireless sensing solutions to Electrochem customers; and

9\. To develop a charging platform for Electrochem’s secondary offering.

\- 28 -

As a result of the investments we have made over the last two years, we are now in a position to provide our OEM customers with full “system” solutions. This includes providing comprehensive products and services, from development and regulatory submissions through manufacturing and supporting worldwide distribution. These systems are niche product solutions that complement our OEM customers’ products and utilize our expertise and capabilities. This strategy includes partnering with our OEM customers, including sharing technology and resources, in order to bring these solutions to market. The benefits to our OEM customers include shortening the time to market for these products by accelerating the velocity of innovation, optimizing their supply chain and ultimately providing them with cost efficiencies.

As previously disclosed, on March 15, 2010 Greatbatch Medical received clearance from the U.S. Food and Drug Administration for its OptiSeal™ Valved PTFE Peelable Introducer. We have also received approval in Canada and OptiSeal™ is CE marked for distribution in Europe. OptiSeal™ represents the first 510(k) regulatory clearance received under the Greatbatch Medical brand and is a result of the significant investments made over the last few years.

OptiSeal™ represents the type of niche “system” level products that we are trying to provide. That is, products that are complementary to the core products of our customers and utilize our expertise and capabilities. OptiSeal™ was developed in collaboration with our OEM customers, leverages our technology and provides our customers with value-added innovative features.

We estimate that the market opportunity for the OptiSeal™ project is approximately $10 — $20 million of annual revenue. Additionally, it provides us with an opportunity for expansion into the vascular and peripheral access markets. In the second half of this year we expect to finalize distribution agreements with our customers and OptiSeal™ will begin to provide a return on the R&D investment we have made over the last two years.

We expect to be able to make additional product announcements later this year after 510(k) regulatory clearance is received. The initial product announcements are expected to center around systems we are developing for the vascular market but longer-term will include our CRM, neuromodulation, Orthopaedics and Electrochem markets. Ultimately our goal is to establish a cadence of system level product announcements similar to the OptiSeal™ Introducer program that will help us achieve our stated goal of growing revenue faster than the underlying markets we serve.

### Cost Savings and Consolidation Efforts

In the 2010 and 2009 periods we recorded charges in Other Operating Expenses, Net in the Condensed Consolidated Statements of Operations related to cost savings and consolidation efforts initiated in 2007 and 2008. These initiatives were undertaken to improve our operational efficiencies and profitability. Additional information regarding the timing, cash flow and amount of future expenditures is set forth in Note 8 “Other Operating Expenses, Net” of the Notes to the Condensed Consolidated Financial Statements contained in this report.

### Our Financial Results

We utilize a fifty-two, fifty-three week fiscal year ending on the Friday nearest December 31st. For 52-week years, each quarter contains 13 weeks. The second quarter of 2010 and 2009 ended on July 2, and July 3, respectively. The commentary that follows should be read in conjunction with our Condensed Consolidated Financial Statements and related notes and with the Management’s Discussion and Analysis of Financial Condition and Results of Operations contained in our Form 10-K for the fiscal year ended January 1, 2010.

\- 29 -

The following table presents certain selected financial information derived from our Condensed Consolidated Financial Statements for the periods presented (dollars in thousands, except per share data):

| Sales: Greatbatch Medical | Three Months Ended July 2, 2010 | July 3, 2009 | $% Change | Change | Six Months Ended July 2, 2010 | July 3, 2009 | $% Change | Change |
| --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| CRM/Neuromodulation | $78,838 | $78,026 | $812 | 1% | $155,763 | $155,293 | $470 | 0% |
| Vascular | 11,007 | 9,152 | 1,855 | 20% | 19,173 | 19,885 | (712) | -4% |
| Orthopaedics | 30,488 | 31,389 | (901) | -3% | 59,929 | 65,472 | (5,543) | -8% |
| Total Greatbatch Medical | 120,333 | 118,567 | 1,766 | 1% | 234,865 | 240,650 | (5,785) | -2% |
| Electrochem | 20,462 | 16,158 | 4,304 | 27% | 37,959 | 33,893 | 4,066 | 12% |
| Total sales | 140,795 | 134,725 | 6,070 | 5% | 272,824 | 274,543 | (1,719) | -1% |
| Cost of sales | 95,336 | 93,253 | 2,083 | 2% | 185,701 | 188,907 | (3,206) | -2% |
| Gross profit | 45,459 | 41,472 | 3,987 | 10% | 87,123 | 85,636 | 1,487 | 2% |
| Gross profit as a % of sales | 32.3% | 30.8% |  |  | 31.9% | 31.2% |  |  |
| Selling, general and administrative expenses (SG&A) | 16,470 | 17,885 | (1,415) | -8% | 32,122 | 36,572 | (4,450) | -12% |
| SG&A as a % of sales | 11.7% | 13.3% |  |  | 11.8% | 13.3% |  |  |
| Research, development and engineering costs, net (RD&E) | 11,177 | 8,694 | 2,483 | 29% | 22,201 | 16,569 | 5,632 | 34% |
| RD&E as a % of sales | 7.9% | 6.5% |  |  | 8.1% | 6.0% |  |  |
| Other operating expenses, net | 495 | 2,424 | (1,929) | -80% | 1,487 | 5,227 | (3,740) | -72% |
| Operating income | 17,317 | 12,469 | 4,848 | 39% | 31,313 | 27,268 | 4,045 | 15% |
| Operating margin | 12.3% | 9.3% |  |  | 11.5% | 9.9% |  |  |
| Interest expense | 5,139 | 4,930 | 209 | 4% | 10,287 | 9,819 | 468 | 5% |
| Interest income | (3) | (2) | (1) | NA | (5) | (27) | 22 | NA |
| Other (income) expense, net | 200 | (604) | 804 | NA | 516 | (397) | 913 | NA |
| Provision for income taxes | 4,193 | 1,583 | 2,610 | 165% | 7,180 | 4,647 | 2,533 | 55% |
| Effective tax rate | 35.0% | 19.4% |  |  | 35.0% | 26.0% |  |  |
| Net income | $7,788 | $6,562 | $1,226 | 19% | $13,335 | $13,226 | $109 | 1% |
| Net margin | 5.5% | 4.9% |  |  | 4.9% | 4.8% |  |  |
| Diluted earnings per share | $0.33 | $0.28 | $0.05 | 18% | $0.57 | $0.56 | $0.01 | 2% |

\- 30 -

### Sales

| Sales: Greatbatch Medical | Three Months Ended July 2, 2010 | July 3,% 2009 | Change | Six Months Ended July 2, 2010 | July 3,% 2009 | Change |
| --- | ---: | ---: | ---: | ---: | ---: | ---: |
| CRM/Neuromodulation | $78,838 | $78,026 | 1% | $155,763 | $155,293 | 0% |
| Vascular | 11,007 | 9,152 | 20% | 19,173 | 19,885 | -4% |
| Orthopaedics | 30,488 | 31,389 | -3% | 59,929 | 65,472 | -8% |
| Total Greatbatch Medical | 120,333 | 118,567 | 1% | 234,865 | 240,650 | -2% |
| Electrochem | 20,462 | 16,158 | 27% | 37,959 | 33,893 | 12% |
| Total sales | $140,795 | $134,725 | 5% | $272,824 | $274,543 | -1% |

***Greatbatch Medical —*** CRM and neuromodulation sales for the three and six months ended July 2, 2010 remained consistent with the prior year periods as the benefit of further adoption of the Company’s Q series batteries, which empower new device features and reduce the overall size of medical devices were offset by lower feedthrough sales as the 2009 periods included the benefit of customer product launches.

Second quarter 2010 sales for the vascular product line increased 20% to $11.0 million, compared to prior year sales of $9.2 million. This increase was primarily due to higher introducer and catheter sales as customer inventory reduction programs, which began in 2009, are now complete and ordering patterns have returned to a more normalized rate. Vascular sales for the first six months of 2010 were 4% below the prior year due to the customer inventory reduction programs mentioned above.

Orthopaedics product line sales of $30.5 million for the second quarter of 2010 were below the $31.4 million for the comparable 2009 period and were negatively impacted by the decline in the euro during the period. Excluding this foreign currency exchange differential, which reduced sales by approximately $1.0 million, orthopaedics revenues were consistent with the prior year. For the year-to-date period orthopaedics sales were 8% below the prior year period due to various customer inventory reduction programs due to lower procedure volumes. However, the impact of these customer inventory reduction initiatives and lower procedure volumes continued to ease during the quarter as orthopaedics sales increased 4% over the sequential first quarter 2010 period. We expect orthopaedics revenue to continue to be impacted by the lower euro exchange rate for the remainder of 2010 and seasonal slow-downs in the third quarter. However these fluctuations are not expected to materially impact our operating income.

***Electrochem —*** Second quarter 2010 sales for the Electrochem business segment were $20.5 million compared to $16.2 million in the second quarter of 2009. The increase from the prior year primarily related to the continued recovery in the energy and portable medical markets. The difficult market conditions experienced in 2009 began to ease in the first quarter 2010 and the second quarter of 2010 saw a restocking of customer inventory, which is not expected to continue in the next two quarters. These strong second quarter sales were also the main driver behind the 12% improvement in Electrochem sales during the first half of 2010 compared to the same period of 2009.

\- 31 -

***2010 Sales Outlook —*** At this time, we expect 2010 annual sales growth by product line to be as follows:

|  |  |  |
| --- | --- | --- |
| **•** | CRM & Neuromodulation | 2% to 5% |
| **•** | Vascular | 3% to 7% |
| **•** | Orthopaedics | 3% to 7% |

- Electrochem 0% to 5%

It is important to note that these annual sales growth rates are on a constant currency basis. As previously discussed, we expect orthopaedics revenue to continue to be negatively impacted by the lower euro foreign currency exchange rate for the remainder of 2010.

### Gross Profit

Changes to gross profit as a percentage of sales from the prior year periods were primarily due to the following:

|  | Changes From Prior Year Three Months | Six Months |
| --- | ---: | ---: |
| Performance-based compensation(a) | 0.3% | 1.0% |
| Excess capacity(b) | -3.5% | -2.6% |
| Selling price(c) | -1.1% | -0.8% |
| Mix Change(d) | 5.0% | 3.9% |
| Other | 0.8% | -0.8% |
| Total percentage point change to gross profit as a percentage of sales | 1.5% | 0.7% |

(a) Amount represents lower performance-based compensation in comparison to the prior year, which is recorded based upon the results of the current period. Performance-based compensation was higher in the second quarter of 2010 versus the sequential first quarter 2010 as revenue and operating results improved. For the remainder of 2010, performance-based compensation is expected to increase as operating results continue to improve.

(b) Our gross profit percentage was negatively impacted from excess capacity costs driven by the lower volumes, primarily for the vascular and orthopaedics product lines, in comparison to the first half of 2009. In accordance with our inventory accounting policy, excess capacity costs are expensed. Excess capacity costs are expected to decrease as volumes improved in the second quarter of 2010.

(c) Our gross profit percentage was negatively impacted due to contractual volume price reductions and price concessions made to our larger OEM customers on certain product lines. We expect this pricing pressure to continue in the future.

(d) Our gross profit percentage was positively impacted from an increase in sales of higher margin products as a percentage of total sales, mainly in CRM and neuromodulation and Electrochem products for the first six months of 2010 and vascular products during the second quarter of 2010.

We expect that our gross profit margin will continue around the second quarter 2010 level for the remainder of the year as sequential sales volume growth is expected to be challenging as discussed above. Over the long-term we expect our gross profit margin to improve as more system level products are introduced, which typically earn a higher margin.

\- 32 -

### SG&A Expenses

Changes to SG&A expenses from the prior year period were due to the following (in thousands):

|  | Changes From Prior Year Three Months | Six Months |
| --- | ---: | ---: |
| Personnel costs(a) | $539 | $(1,384) |
| Litigation related fees and charges(b) | (1,147) | (1,031) |
| Allowance for doubtful accounts(c) | (474) | (1,394) |
| Other | (333) | (641) |
| Net decrease in SG&A | $(1,415) | $(4,450) |

(a) Amount represents the change in personnel costs from the 2009 period and includes the impact of performance-based compensation as well as our consolidation and cost cutting initiatives. Performance-based compensation varies based upon the results for the period and was higher in the second quarter of 2010 versus the sequential first quarter 2010 as revenue and operating results improved. For the remainder of 2010, performance-based compensation is expected to increase as operating results continue to improve.

(b) Amounts represent the change in fees and charges incurred versus the 2009 period in connection with the patent infringement action filed by Pressure Products and the Electrochem Litigation discussed in Note 10 “Commitments and Contingencies” of the Notes to the Condensed Consolidated Financial Statements contained in this report.

(c) Amounts primarily relate to lower losses incurred on uncollectible receivables compared to the 2009 period, which included higher Electrochem and orthopaedics write-offs due to the economic slowdown.

Throughout the remainder of 2010, we expect SG&A expenses to increase slightly from the current levels due to normal inflationary cost increases, investment in sales and marketing and higher performance-based compensation as our operating results improve.

### RD&E Expenses, Net

Net RD&E costs are comprised of the following (in thousands):

|  | Three Months Ended July 2, 2010 | July 3, 2009 | Six Months Ended July 2, 2010 | July 3, 2009 |
| --- | ---: | ---: | ---: | ---: |
| Research and development costs | $4,426 | $4,725 | $8,954 | $8,736 |
| Engineering costs | 8,804 | 6,333 | 16,817 | 12,779 |
| Less cost reimbursements | (2,053) | (2,364) | (3,570) | (4,946) |
| Engineering costs, net | 6,751 | 3,969 | 13,247 | 7,833 |
| Total RD&E | $11,177 | $8,694 | $22,201 | $16,569 |

\- 33 -

As expected, net RD&E expenses for the first two quarters of 2010 were above the comparable 2009 period due to further investment in the development of new technologies, including the development of systems level solutions. Additionally, during 2010 we received a lower level of customer cost reimbursements. These cost reimbursements can vary significantly from period to period due to the timing of the achievement of milestones on development projects. Excluding these customer cost reimbursements, RD&E was 9.4% of sales for the first six months of 2010 compared to 7.8% of sales in the comparable 2009 period. We anticipate that the higher level of RD&E investment will continue for the remainder of 2010 consistent with our long-term growth strategy. Our long-term growth strategy includes investing resources in new technologies, including system level solutions for our customers. This strategy also includes partnering with our OEM customers, including sharing technology and resources, in order to bring these solutions to market. The benefits to our OEM customers is that it will shorten their time to market by accelerating the velocity of innovation, optimizing their supply chain and ultimately providing them with cost efficiencies. The timeline for approval of our vascular market systems projects is shorter than for our other markets. As such, we anticipate making additional announcements, similar to the OptiSealTM project discussed in the Product Development section of this report, over the next several quarters.

### Other Operating Expenses, Net

Other operating expenses, net is comprised of the following (in thousands):

|  | Three Months Ended July 2, 2010 | July 3, 2009 | Six Months Ended July 2, 2010 | July 3, 2009 |
| --- | ---: | ---: | ---: | ---: |
| 2007 & 2008 facility shutdowns and consolidations(a) | $536 | $1,578 | $856 | $3,477 |
| Integration costs(b) | 8 | 717 | 130 | 1,580 |
| Asset dispositions and other(c) | (49) | 129 | 501 | 170 |
|  | $495 | $2,424 | $1,487 | $5,227 |

(a) In the 2010 and 2009 periods, we recorded charges related to our various cost savings and consolidation efforts initiated in 2007 and 2008. Over the long-term, we expect these initiatives to improve our operational efficiencies and profitability. During the second quarter of 2010, the Company recognized a $0.6 million write down related to its Electrochem facility, as the estimated fair value less costs to sell was below the recorded book value. Additional information regarding the timing, cash flow and amount of future expenditures is discussed in Note 8 “Other Operating Expenses, Net” of the Notes to the Condensed Consolidated Financial Statements contained in this report. At this time, we have completed all of our publicly announced consolidation initiatives. However, we continually analyze our business to find ways to improve our operational efficiency and we expect to take additional steps to drive further improvements, particularly with respect to the optimization of our orthopaedics product line. During the current quarter, this optimization plan, which will be ongoing for the next several years, continued and was primarily focused on our Indianapolis, Indiana facility.

(b) During the 2010 and 2009 periods, we incurred costs related to the integration of the companies acquired in 2007 and 2008. The integration initiatives include the implementation of the Oracle ERP system, training and compliance with policies, as well as the implementation of lean manufacturing and six sigma initiatives. The expenses are primarily for consultants, relocation and travel costs that will not be required after the integrations are completed.

(c) During the 2010 and 2009 periods, we recorded write-downs in connection with various asset disposals.

In 2010, consolidation and integration expenses are expected to be approximately $4 to $6 million.

\- 34 -

### Interest Expense and Interest Income

Interest expense and interest income for the first two quarters of 2010 were consistent with the same periods of 2009. Going forward, we expect interest expense to remain at current levels as the benefit of paying down our long-term debt with excess cash flow from operations is expected to be offset by increased discount amortization and interest expense associated with the Electrochem Litigation appeal. See Note 10 “Commitments and Contingencies” of the Notes to Condensed Consolidated Financial Statements in this report.

### Other (Income) Expense, Net

Other (income) expense, net primarily includes the impact of foreign currency exchange rate fluctuations on transactions denominated in foreign currencies, which did not materially impact our results in the first two quarters of 2010 or 2009. The Company generally does not expect foreign currency exchange rate fluctuations to have a material impact on its net income.

### Provision for Income Taxes

The effective tax rate for the three and six months ended July 2, 2010 was 35.0% compared to 19.4% and 26.0%, respectively, for the comparable 2009 periods. The current period rate reflects a tax benefit from having operations outside the U.S., which are taxed at rates lower than the U.S. statutory rate of 35%. This benefit was offset by the impact of non-deductible items and the absence of the research and development tax credit, which expired at the end of 2009. The second quarter 2009 tax rate also included the favorable impact of the resolution of tax audits. Pending legislation would retroactively reinstate the R&D tax credit to the beginning of 2010. This legislation, if enacted, would positively impact the effective tax rate in the period that it is enacted.

We believe that it is reasonably possible that a reduction of approximately $0.7 million of the balance of unrecognized tax benefits may occur within the next twelve months as a result of the expiration of applicable statutes of limitation, which would positively impact our effective tax rate in the period of reduction.

### Liquidity and Capital Resources

*(Dollars in thousands)*

|  | As of July 2, 2010 | January 1, 2010 |
| --- | ---: | ---: |
| Cash and cash equivalents(a) | $45,657 | $37,864 |
| Working capital(a) | $162,878 | $119,926 |
| Current ratio(a) | 2.6 | 1.9 |

(a) These increases primarily relate to the cash flow generated from operations of $44.2 million for the first half of 2010 partially offset by net expenditures for property, plant and equipment of $6.4 million. Additionally, our current ratio benefited from the $30.5 million payoff of the current portion of our long-term debt that came due during the second quarter of 2010.

\- 35 -

***Revolving Line of Credit —*** We have a senior credit facility (the “Credit Facility”) consisting of a $235 million revolving line of credit, which can be increased to $335 million upon our request and approval by a majority of the lenders. The Credit Facility also contains a $15 million letter of credit subfacility and a $15 million swingline subfacility. In connection with the Electrochem Litigation, we were required to bond the amount of the judgment and statutory interest in order to appeal. We satisfied this requirement by posting a bond, which required collateralization. We received approval from the lenders supporting our Credit Facility to increase the letter of credit subfacility by $35 million for use only in connection with bonding the appeal of the Electrochem Litigation, of which $23 million was being utilized as of July 2, 2010. The Credit Facility is secured by our non-realty assets including cash, accounts and notes receivable, and inventories, and has an expiration date of May 22, 2012 with a one-time option to extend to April 1, 2013 at our option if no default has occurred.

The Credit Facility is supported by a consortium of six banks with no bank controlling more than 25% of the facility. As of July 2, 2010, each bank supporting the Credit Facility has an S&P credit rating of at least BBB- or better, which is considered investment grade.

The Credit Facility requires us to maintain a ratio of adjusted EBITDA, as defined in the credit agreement, to interest expense of at least 3.00 to 1.00. For the twelve month period ending July 2, 2010, our ratio of adjusted EBITDA to interest expense, calculated in accordance with our credit agreement, was 9.3 to 1.00, well above the required limit. The Credit Facility also requires us to maintain a total leverage ratio, as defined in the credit agreement, of not greater than 4.50 to 1.00. As of July 2, 2010, our total leverage ratio, calculated in accordance with our credit agreement, was 3.04 to 1.00, well below the required limit. The calculation of adjusted EBITDA and leverage ratio exclude non-cash charges, as well as charges in connection with the Electrochem Litigation up to a limit of $35 million.

The Credit Facility contains customary events of default. Upon the occurrence and during the continuance of an event of default, a majority of the lenders may declare the outstanding advances and all other obligations under the Credit Facility immediately due and payable. See Note 5 “Debt” of the Notes to Condensed Consolidated Financial Statements in this report for a more detailed description of the Credit Facility.

Based upon our current capital needs, we anticipate utilizing free cash flow (cash flow from operations less capital expenditures) to make principal payments on our long-term debt. In July 2010, we made an additional $20 million payment on the outstanding balance under the Credit Facility. As of July 2, 2010, we had $114 million of borrowing capacity available under the Credit Facility. This amount may vary from period to period based upon our debt and EBITDA levels, which impacts the covenant calculations. We believe that our cash flow from operations and the Credit Facility provide adequate liquidity to meet our short- and long- term funding needs.

***Operating activities —*** Cash flows from operations for the first six months of 2010 were $44.2 million compared to $21.7 million for the comparable 2009 period. The increase from the prior year is primarily due to our strategic initiatives designed to improve operational efficiency, as well as the timing of payments and lower consolidation and integrations costs.

***Investing activities —*** Net cash used in investing activities for the first six months of 2010 were $5.6 million and was primarily related to maintenance capital expenditures. Our current expectation is that capital spending for the remainder of 2010 will be in the range of $10 million to $20 million, of which approximately half is discretionary in nature. These purchases relate to routine maintenance investments to support our internal growth, as well as additional investment in our orthopaedics business in order to further drive operational efficiencies.

We anticipate that cash on hand along with cash flow from operations and availability under our revolving line of credit will be sufficient to fund these capital expenditures. Going forward, we will continue to consider strategically targeted and opportunistic acquisitions.

\- 36 -

***Financing activities —*** Net cash used in financing activities for the first six months of 2010 were $30.5 million. As expected, during the second quarter of 2010 the holders of the remaining $30.5 million of CSN I notes exercised their put option. These notes were repaid with cash on hand. Going forward, we expect excess cash flow to be used to pay down amounts outstanding under our revolving line of credit and we made a $20 million principal payment in July 2010.

***Capital Structure —*** As of July 2, 2010, our capital structure consisted of $197.8 million of convertible subordinated notes, $98.0 million of debt under our revolving line of credit and 23.2 million shares of common stock outstanding. Additionally, we had $45.7 million in cash and cash equivalents, which is sufficient to meet our short-term operating cash needs. If necessary, we have access to $114 million of borrowing capacity under our line of credit and are authorized to issue up to 100 million shares of common stock and 100 million shares of preferred stock. The market value of our outstanding common stock since our initial public offering has exceeded our book value; accordingly, we believe that if needed we can access public markets to raise additional capital. Our capital structure allows us to support our internal growth and provides liquidity for corporate development initiatives. We continually assess our financing facilities and capital structure to ensure liquidity and capital levels are sufficient to meet our strategic objectives. In the future, we may adjust our capital structure as funding opportunities present themselves.

### Off-Balance Sheet Arrangements

We have no off-balance sheet arrangements within the meaning of Item 303(a)(4) of Regulation S-K.

### Contractual Obligations

The following table summarizes our significant contractual obligations at July 2, 2010:

| CONTRACTUAL OBLIGATIONS | Payments due by period Total | Remainder of 2010 | 2011 - 2012 | 2013 - 2014 | After 2014 |
| --- | ---: | ---: | ---: | ---: | ---: |
| Debt obligations(a) | $316,472 | $4,150 | $112,315 | $200,007 | $— |
| Operating lease obligations(b) | 15,451 | 1,501 | 3,935 | 3,609 | 6,406 |
| Purchase obligations(b) | 10,437 | 10,178 | 259 | — | — |
| Foreign currency contracts(b) | 4,500 | 4,500 | — | — | — |
| Pension obligations(c) | 10,632 | 412 | 1,975 | 2,272 | 5,973 |
|  | $357,492 | $20,741 | $118,484 | $205,888 | $12,379 |

(a) Includes the annual interest expense on our convertible subordinated notes of 2.25%, which is paid semi-annually. Amounts also include the expected interest expense on the $98.0 million outstanding on our line of credit based upon the period end weighted average interest rate of 3.9%, which includes the impact of our interest rate swaps outstanding. See Note 5 “Debt” of the Notes to Condensed Consolidated Financial Statements in this report for additional information about our debt obligations.

(b) See Note 10 “Commitments and Contingencies” of the Notes to Condensed Consolidated Financial Statements in this report for additional information about our operating lease, purchase obligations and foreign currency contracts.

\- 37 -

(c) See Note 6 “Pension Plans” of the Notes to Condensed Consolidated Financial Statements in this report for additional information about our pension plan obligations. These amounts do not include any potential future contributions to our pension plan that may be necessary if the rate of return earned on pension plan assets is not sufficient to fund the rate of increase of our pension liability. Future cash contributions may be required. As of January 1, 2010, the most recent valuation date, our actuarially determined pension benefit obligation exceeded the plans assets by $4.0 million.

This table does not reflect $3.4 million of unrecognized tax benefits as we are uncertain as to if or when such amounts may be settled. Refer to Note 9 “Income Taxes” of the Notes to Condensed Consolidated Financial Statements in this report for additional information about these unrecognized tax benefits. Additionally, the table does not include any potential payments that may be due in connection with the Electrochem Litigation (See Note 10 “Commitments and Contingencies” of the Notes to Condensed Consolidated Financial Statements contained in this report).

In an attempt to help offset the cost of rising health care expenses, beginning in 2010, we began self-funding the medical insurance coverage for all of our U.S. based employees. Our risk is being limited through the use of stop loss insurance which has deductibles in the amount of $0.2 million per covered participant and $9.9 million in the aggregate per year. The maximum benefit for aggregate losses is $1.0 million and $4.8 million for specific losses. As of July 2, 2010, we have $2.2 million accrued related to the self-insurance of our medical plan, which is recorded as Accrued Expenses and Other Current Liabilities in the Condensed Consolidated Balance Sheet and is not included in the contractual obligations table above.

### Impact of Recently Issued Accounting Standards

In the normal course of business, we evaluate all new accounting pronouncements issued by the Financial Accounting Standards Board (“FASB”), Securities and Exchange Commission (“SEC”), Emerging Issues Task Force (“EITF”), American Institute of Certified Public Accountants (“AICPA”) or other authoritative accounting body to determine the potential impact they may have on our Consolidated Financial Statements. Based upon this review, we do not expect any of the recently issued accounting pronouncements, which have not already been adopted, to have a material impact on the Company’s Consolidated Financial Statements.

### Forward-Looking Statements

Some of the statements contained in this report and other written and oral statements made from time to time by us and our representatives are not statements of historical or current fact. As such, they are “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. We have based these forward-looking statements on our current expectations, which are subject to known and unknown risks, uncertainties and assumptions. They include statements relating to:

- future sales, expenses and profitability;
- the future development and expected growth of our business and the markets we operate in;
- our ability to successfully execute our business model and our business strategy;
- our ability to identify trends within the implantable medical devices, medical components, and Electrochem markets and to offer products and services that meet the changing needs of those markets;
- projected capital expenditures; and
- trends in government regulation, including the impact of Health Care Reform.

\- 38 -

You can identify forward-looking statements by terminology such as “may,” “will,” “should,” “could,” “expects,” “intends,” “plans,” “anticipates,” “believes,” “estimates,” “predicts,” “potential” or “continue” or the negative of these terms or other comparable terminology. These statements are only predictions. Actual events or results may differ materially from those suggested by these forward-looking statements. In evaluating these statements and our prospects generally, you should carefully consider the factors set forth below. All forward-looking statements attributable to us or persons acting on our behalf are expressly qualified in their entirety by these cautionary factors and to others contained throughout this report. We are under no duty to update any of the forward-looking statements after the date of this report or to conform these statements to actual results.

Although it is not possible to create a comprehensive list of all factors that may cause actual results to differ from the results expressed or implied by our forward-looking statements or that may affect our future results, some of these factors include the following: dependence upon a limited number of customers, product obsolescence, inability to market current or future products, pricing pressure from customers, reliance on third party suppliers for raw materials, products and subcomponents, fluctuating operating results, inability to maintain high quality standards for our products, challenges to our intellectual property rights, product liability claims, inability to successfully consummate and integrate acquisitions, unsuccessful expansion into new markets, competition, inability to obtain licenses to key technology, regulatory changes or consolidation in the healthcare industry, and other risks and uncertainties that arise from time to time as described in the Company’s Annual Report on Form 10-K and other periodic filings with the Securities and Exchange Commission.

## Market risk

As filed, 3,741 characters.

***Foreign Currency —*** We have significant foreign operations in France, Mexico and Switzerland, which expose the Company to foreign currency exchange rate fluctuations due to transactions denominated in Euros, Pesos and Swiss Francs, respectively. We continuously evaluate our foreign currency risk and will take action from time to time in order to best mitigate these risks, which includes the use of various derivative instruments such as forward currency exchange contracts. See Note 10 “Commitments and Contingencies” of the Notes to Condensed Consolidated Financial Statements in this report for additional information about our forward currency exchange contracts. A hypothetical 10% change in the value of the U.S. dollar in relation to our most significant foreign currency exposures would have had an impact of approximately $8 million on our annual sales. This amount is not indicative of the hypothetical net earnings impact due to partially offsetting impacts on cost of sales and operating expenses in those currencies.

We translate all assets and liabilities of our foreign operations, where the U.S. dollar is not the functional currency, at the period-end exchange rate and translate sales and expenses at the average exchange rates in effect during the period. The net effect of these translation adjustments is recorded in the Condensed Consolidated Financial Statements as Comprehensive Income (Loss). The cumulative translation adjustment as of July 2, 2010 was a $0.3 million loss. Translation adjustments are not adjusted for income taxes as they relate to permanent investments in our foreign subsidiaries. Net foreign currency transaction gains and losses included in Other Expense, Net amounted to a loss of $0.5 million and gain of $0.5 million for the first six months of 2010 and 2009, respectively. A hypothetical 10% change in the value of the U.S. dollar in relation to our most significant foreign currency net assets would have had an impact of approximately $9 million on our foreign net assets as of July 2, 2010.

\- 39 -

***Interest Rate Swaps —*** As of July 2, 2010, we had $98 million outstanding on our revolving line of credit. Interest rates reset on this debt based upon the six-month LIBOR rate, thus subjecting us to interest rate risk. During 2008, we entered into three receive floating-pay fixed interest rate swaps indexed to the six-month LIBOR rate. The objective of these swaps is to hedge against potential changes in cash flows on our outstanding revolving line of credit. No credit risk was hedged. The receive variable leg of the swaps and the variable rate paid on the revolving line of credit bear the same rate of interest, excluding the credit spread, and reset and pay interest on the same dates. See Note 5 “Debt” of the Notes to Condensed Consolidated Financial Statements in this report for additional information about our interest rate swap contracts.

The estimated negative fair value of the interest rate swap contracts of $0.8 million as of July 2, 2010 represents the amount we would have to pay to terminate the contracts. No portion of the change in fair value of the interest rate swaps during the 2010 or 2009 periods was considered ineffective. The amount recorded as additional Interest Expense related to the interest rate swaps for the second quarter of 2010 and 2009 was $0.6 million and $0.3 million, respectively, and $1.2 million and $0.5 million, respectively, for the six months ended July 2, 2010 and July 3, 2009.

Any change in the LIBOR interest rate would not have an impact on our interest expense relating to the $98 million of floating rate revolving line of credit debt outstanding due to the interest rate swap agreements we have in place.

## Controls and procedures

As filed, 1,387 characters.

a. Evaluation of Disclosure Controls and Procedures.

Our management, including the principal executive officer and principal financial officer, evaluated our disclosure controls and procedures (as defined in Rules 13a-15(e) and 15d-15(e) under the Securities Exchange Act of 1934) related to the recording, processing, summarization and reporting of information in our reports that we file with the SEC as of July 2, 2010. These disclosure controls and procedures have been designed to provide reasonable assurance that material information relating to us, including our subsidiaries, is made known to our management, including these officers, by other of our employees, and that this information is recorded, processed, summarized, evaluated and reported, as applicable, within the time periods specified in the SEC’s rules and forms. Based on their evaluation, as of July 2, 2010, our principal executive officer and principal financial officer have concluded that our disclosure controls and procedures are effective.

b. Changes in Internal Control Over Financial Reporting.

There have been no changes in our internal control over financial reporting that occurred during our last fiscal quarter to which this Quarterly Report on Form 10-Q relates that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.

\- 40 -

## Risk factors

As filed, 140 characters.

There have been no material changes from risk factors as previously disclosed in the Company’s Form 10-K for the year ended January 1, 2010.

Filed Aug 10, 2010.
Source: SEC EDGAR, the filing index for accession 0000950123-10-075320. Last ingested by Listed: Nov 11, 2026, 00:08 ET. No prices; not investment advice.
